The indication makes insulin icodec the first new class of basal insulin to reach US patients in more than 2 decades.

The US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly basal insulin available in the US, as an adjunct to diet and exercise to improve glycemic control in adults with 

The decision makes insulin icodec the first new class of basal insulin to reach US patients in more than 2 decades.

FDA issued a Complete Response Letter (CRL)

 to Novo Nordisk for once-weekly basal insulin icodec, with requests concerning the manufacturing process and the type 1 diabetes (T1D) indication, which were required to be addressed before the BLA review could be completed. Importantly, the May 2024 

 against concluding that the benefits of insulin icodec outweigh its risks was specific to T1D; the committee did not evaluate its use for type 2 diabetes. 

Novo Nordisk resubmitted the BLA in late September 2025, based on results from the 

 type 2 diabetes phase 3A program, which comprised 5 randomized, active-controlled, treat-to-target clinical trials in approximately 4000 adults with T2D. Today's approval is the outcome of that resubmission, and it is limited to adults with T2D — a population where the clinical evidence was consistently robust throughout the regulatory review.

The approval rests on results from four of the ONWARDS trials: large, active-controlled, treat-to-target studies evaluating insulin icodec head-to-head against standard once-daily basal insulins, including insulin glargine U100 and insulin degludec.

ONWARDS 1, a 78-week trial in 984 insulin-naive adults with T2D and inadequate glycemic control, demonstrated a mean HbA1c reduction of –1.55% with once-weekly insulin icodec compared to –1.35% with once-daily insulin glargine U100.

ONWARDS 3 assessed insulin icodec against insulin degludec in combination with non-insulin antidiabetes treatments in insulin-naive adults with T2D, achieving a mean HbA1c reduction of –1.57% in the icodec group versus –1.36% in the degludec group at week 26. 

ONWARDS 4, which evaluated icodec in combination with mealtime insulin in adults with T2D, demonstrated noninferiority to insulin glargine U100, with mean HbA1c reductions of –1.16% and –1.18%, respectively, at week 26. 

ONWARDS 5, a 52-week real-world-design trial that utilized a dosing guide app for uptitration, demonstrated the largest separation from the comparator arm: a mean HbA1c reduction of –1.68% with insulin icodec versus –1.31% for once-daily basal insulin analogues.

Taken together, a published meta-analysis of the ONWARDS phase 3 program supports these findings. Across 5 randomized controlled trials enrolling 3764 participants, once-weekly insulin icodec demonstrated a statistically significant incremental HbA1c reduction compared to once-daily basal insulin analogues (mean difference, –0.17%; 95% CI, –0.28 to –0.06; 

 = .003), and a higher proportion of patients achieved HbA1c below 7% with icodec than with comparators (OR, 1.51; 95% CI, 1.14 – 1.99; 

In ONWARDS 1, insulin icodec allowed people to spend significantly more time in range compared with once-daily insulin glargine U100, with comparable time below range — a finding that ONWARDS principal investigator Julio Rosenstock, MD, Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, described as 

demonstrating the potential to change how T2D requiring basal insulin is treated.

Prescribers should note that icodec's pharmacokinetic profile introduces a nuanced hypoglycemia consideration. Patients treated with Awiqli tended to have a greater incidence of hypoglycemic events, particularly on days 2 - 4 of the weekly dosing cycle, which corresponds to the 

pharmacokinetic profile for insulin icodec

 where exposure is highest early in the week. 

In ONWARDS 3, combined level 2 or 3 hypoglycemia rates were statistically higher in the icodec group from week 0 to 26 (0.35 vs. 0.12 events per patient-year exposure; 

 = .01), though absolute rates were less than one event per patient-year in both arms. 

This pattern was consistent across trials and should be incorporated into patient education, particularly for those at elevated hypoglycemia risk, such as older adults or those with renal impairment.

Patient and Physician Satisfaction Signal

Beyond glycemic efficacy, real-world uptake of a new insulin formulation often hinges on patient experience. In ONWARDS 2 and 5, patient treatment satisfaction was significantly higher with once-weekly icodec than with once-daily comparators, driven primarily by willingness to continue and recommend the therapy; in ONWARDS 2, 93.7% of icodec users preferred the once-weekly regimen, citing less frequent injections and ease of use. 

Physician satisfaction data from ONWARDS 1 pointed in the same direction, with investigators more likely to recommend the weekly option.

"Research supports weekly injectable diabetes medications can be associated with improved patient adherence," said Rosenstock at the time. "Having a weekly basal insulin option like insulin icodec-abae may reshape insulin management in adults with type 2 diabetes, giving them a routine that feels more manageable as they work toward their blood sugar goals."

Awiqli is administered subcutaneously once weekly on the same calendar day each week using the Awiqli FlexTouch pen. The product is formulated at a concentration of 700 units/mL (U-700) — substantially more concentrated than standard U-100 formulations such as insulin glargine — and this distinction carries meaningful dosing error implications.

The prescribing information includes explicit warnings against using a syringe to withdraw insulin from the pen, dialing the maximum single dose of 700 units unless specifically prescribed, and mixing or diluting the product with any other insulin.

Common adverse effects include hypoglycemia, injection-site reactions, lipodystrophy, pruritus, rash, peripheral edema, and weight gain. Clinicians prescribing concomitant thiazolidinediones (TZDs) should counsel patients on the risk of fluid retention and potential worsening of heart failure.

2026 has already proven to be an eventful year for diabetes pharmacotherapy. 

 introduced new guidelines for GLP-1 usage, insulin pump access, and continuous glucose monitoring, promoting comprehensive diabetes management — a broader shift in which once-weekly basal insulin now fits as an additional tool for personalizing the treatment regimen.

Awiqli is expected to be available nationwide in US pharmacies in the coming months.

Novo Nordisk. Awiqli (insulin icodec-abae) [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2026.

Novo Nordisk Resubmits Insulin Icodec (Awiqli) Injection BLA for Type 2 Diabetes. HCPLive. February 2026. 

https://www.hcplive.com/view/novo-nordisk-resubmits-insulin-icodec-awiqli-injection-bla-for-type-2-diabetes

FDA Issues Complete Response Letter for Once-Weekly Insulin Icodec. HCPLive. July 2024. 

https://www.hcplive.com/view/fda-issues-complete-response-letter-for-once-weekly-insulin-icodec

Once-Weekly Insulin Icodec Improves Time in Range, Glycemic Control Better than Daily Insulin Degludec. HCPLive. 

https://www.hcplive.com/view/once-weekly-insulin-icodec-improves-time-in-range-glycemic-control-better-than-daily-insulin-degludec

Rosenstock J, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389(16):1533.

Philis-Tsimikas A, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated type 2 diabetes (ONWARDS 2). Lancet Diabetes Endocrinol. 2023.

Lingvay I, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330(3):228–237.

Mathieu C, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in basal-bolus insulin-treated type 2 diabetes (ONWARDS 4). Lancet. 2023.

American Diabetes Association Professional Practice Committee. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1):S89–S131.

Articles

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

FDA News

Type 2 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes

Janiene Luke, MD, is a clinical professor and residency program director
at the department of dermatology for Loma Linda University Medical Center.

Addressing Complex Cases in Dermatology at SOCS Scientific Symposium, With Janiene Luke, MD

 team spoke in an interview at the 22nd Annual Skin of Color Society (SOCS) Scientific Symposium, held in conjunction with the 

2026 American Academy of Dermatology (AAD) Annual Meeting

, with Janiene D. Luke, MD, clinical professor and residency program director at the Loma Linda University’s Department of Dermatology.

Luke, co-chair of the Scientific Symposium, provided 

 with her perspective on the forces that molded this year's program and what attendees can expect. She also highlighted several of the key topics highlighted in sessions at the meeting, including complex cases in dermatology.

“We worked really hard on trying to come up with a theme that would really encapsulate the times that we're facing in our current state,” Luke explained.

Luke touched on the thinking behind the symposium's theme of championing evidence-based dermatology and collaborative opportunities in medicine. She described the organizing committee’s work in deliberately capturing what she described as the current state of medicine. Luke emphasized the centering of the dermatologist as a hub for collaboration across specialties and services.

On the collaboration piece specifically, Luke was clear that the motivation was holistic patient care. The individual in front of a clinician is rarely defined solely by their diagnosis, Luke noted, and barriers to care, including social, environmental, systemic barriers, can shape the ways in which patients experience and carry through their treatment. Addressing such barriers can mean reaching beyond dermatology, whether to social services, other specialists, or community resources, she expressed.

Luke was also asked about complex cases in dermatology, pointing to hidradenitis suppurativa (HS) and gender-affirming care as 2 notable areas the symposium would address directly. Additionally, she pointed to other challenging conditions that require dermatologists to meet patients where they are and deliver quality care across varying circumstances.

When it came to sessions she was particularly looking forward to, Luke highlighted the keynote from former US Surgeon General Regina Benjamin, MD, whose background in public health, health equity, and health policy made her a natural fit for the symposium’s themes. She was especially drawn to Benjamin's personal story of overcoming obstacles to deliver care in underserved communities.

Annual Scientific Symposium. Skin of Color Society. Accessed March 26, 2026. 

https://skinofcolorsociety.org/what-we-do/education/annual-scientific-symposium

Doctor Profiles. Skin of Color Society. Accessed March 26, 2026. 

https://skinofcolorsociety.org/events/dr-profiles/janiene-luke-md-faad

Videos

Janiene Luke, MD, co-chair of the Skin of Color Society (SOCS) Scientific Symposium, speaks about complex cases in dermatology and other topics covered at the meeting.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Barbara Gillespie, MD, is Chief Medical and Strategy Officer of the International Society of Glomerular Disease and Adjunct Professor at the University of North Carolina.

Tobias Huber, MD, is President of the International Society of Glomerular Disease, Chair of the Center of Internal Medicine; Director of the III. Department of Medicine (Nephrology, Rheumatology, Endocrinology and Transplantation); and Director of the Hamburg Center for Kidney Health at the University Medical Center Hamburg-Eppendorf.

Rapid developments in glomerular disease in the past 5 years have warranted evolving approaches to clinical trial design, identifying new biomarkers, and redefining kidney care.

This research is reshaping the understanding and treatment of APOL1-mediated kidney disease, membranous nephropathy, and IgA nephropathy, along with adding to global efforts to refine clinical trial endpoints and accelerate therapeutic development, underscoring key challenges and breakthroughs in the field.

In this Q&A, Barbara Gillespie, MD, and Tobias Huber, MD, discuss advances in glomerular disease research and care at the International Society of Glomerular Disease (ISGD), including biomarker discovery, molecular technologies, and emerging targeted therapies

Both Huber and Gillespie emphasized the importance of collaboration across institutions, societies, and stakeholders, highlighting initiatives such as ISGD and PARASOL as examples of how shared frameworks are accelerating progress in glomerular disease research and care.

: What have been the most significant inflection points in glomerular disease research over the past five years?

Huber: The last five years have been the most dynamic period in glomerular disease research to date. Advances in single-cell and spatial technologies have significantly deepened understanding of disease biology, enabling higher-resolution stratification and identification of new biomarkers. This has improved diagnostic precision, including the emergence of autoantibodies such as anti-nephrin antibodies, which are increasingly linked to specific glomerular diseases.

Therapeutically, the field has also seen multiple successful Phase 3 trials across complement-mediated diseases, B-cell–mediated diseases, IgA nephropathy, and emerging modalities such as CAR T-cell–based approaches in lupus nephritis. In parallel, the creation of the International Society of Glomerular Disease has helped align academia, industry, and regulators, facilitating initiatives such as PARASOL to identify surrogate endpoints like proteinuria in FSGS.

: How has APOL1-mediated kidney disease influenced both research and clinical trial design?

Gillespie: APOL1 has been a major example of how genetic discoveries translate into clinical development. Early work through the Kidney Health Initiative helped establish a roadmap for APOL1 therapeutic programs. However, conducting trials in this space requires meaningful engagement with patients and communities that have historically been underrepresented and, in many cases, have appropriate levels of distrust toward the medical system.

One key lesson has been the importance of meeting patients where they are. In some communities, that has meant engaging faith leaders and churches as trusted sources of education around kidney disease and clinical trials. In one example, outreach through a church-based initiative resulted in nearly all congregants agreeing to be screened for a clinical trial, highlighting the importance of trust and community engagement.

The broader goals have included raising awareness of kidney disease in Black Americans, increasing screening, and improving clinical trial participation. With APOL1 variants identified in 2011, the field has progressed rapidly into Phase 2 and Phase 3 development, demonstrating how quickly precision nephrology can advance when biological targets are well defined.

: How are emerging biomarkers such as anti-nephrin antibodies changing disease classification and management?

Huber: Anti-nephrin antibodies represent a shift toward a more precise understanding of diseases such as minimal change disease, which historically lacked a clear mechanistic basis. Evidence now suggests that a large proportion of adult minimal change disease and even pediatric idiopathic nephrotic syndrome may be driven by autoantibodies.

This has implications for diagnosis, prognosis, and therapeutic decision-making. It also supports a shift away from prolonged steroid exposure toward more targeted B-cell–modulating or depleting therapies. However, a major limitation is that testing remains largely confined to academic centers, and broader clinical adoption will require standardized, commercially available assays.

Clinically, these antibodies may also help guide treatment monitoring and, in some cases, pre-transplant management in patients at high risk of recurrence.

: How is membranous nephropathy informing the development of surrogate endpoints in glomerular disease?

Gillespie: Membranous nephropathy has become a model for precision nephrology, particularly with PLA2R-positive disease, which accounts for approximately 75% to 80% of cases. The availability of measurable antibodies has allowed clinicians to directly link diagnosis, treatment response, and disease activity.

Through PARASOL initiatives, the field is now working to refine surrogate endpoints beyond proteinuria alone by integrating antibody dynamics. This approach may improve trial design and better reflect disease biology. However, a major challenge remains ensuring that antibody measurements are consistently incorporated into clinical trials and registries.

Without that data, opportunities to improve endpoint validation and regulatory pathways are missed.

: How are clinical trial design and execution evolving in glomerular disease?

Gillespie: Clinical trial design has improved significantly, particularly in defining disease-specific endpoints rather than applying a one-size-fits-all approach across glomerular diseases. However, execution remains a challenge, especially in patient recruitment.

Community nephrologists are increasingly central to trial enrollment, and efforts such as clinical trial boot camps aim to expand participation beyond academic centers. This is critical as the number of trials grows and earlier diagnosis increases the pool of potential participants.

Looking ahead, successful trial programs will require not only strong design but also broad engagement across academic and community practice settings.

: What are the key priorities for glomerular disease research heading into 2026?

Huber: Future priorities include continued implementation of surrogate endpoints, refinement of disease-specific trial designs, and improved molecular stratification of glomerular diseases. Advances in molecular imaging and biopsy analysis are expected to shift classification toward true disease endotypes.

Gillespie: There is also growing interest in hierarchical composite endpoints that integrate both clinical and patient-reported outcomes. In addition, the field is moving toward more collaborative models of drug development, including shared data initiatives and cross-industry cooperation.

Other emerging areas include cell and gene therapy, as well as expanded collaboration with specialties such as hematology and oncology, particularly as these modalities enter nephrology.

Editors’ Note: Gillespie reports no relevant disclosures. Huber reports relevant disclosures with Boehringer Ingelheim, Novartis, Alexion, Pfizer, Retrophin-Travere, and Fresenius Medical Care.

Hopper T, Olabisi OA. APOL1-Mediated Kidney Disease. JAMA. 2024;331(19):1668–1669. doi:10.1001/jama.2024.2667.

Vasquez-Rios G, et al. Novel Therapies in APOL1-Mediated Kidney Disease. Kidney Int Rep. 2023. doi:10.1016/j.ekir.2023.08.028.

Experts discuss major advances in glomerular disease research and care, including molecular technologies, biomarker discovery, APOL1-mediated kidney disease, and evolving clinical trial design and endpoints.

Strategic Alliance Partnership

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

From APOL1 to Biomarkers, Glomerular Disease Research Is Redefining Kidney Care, With Tobias Huber, MD, Barbara Gillespie, MD

Temitayo Ogunleye, MD, is a professor of Clinical Dermatology at the University of Pennsylvania. She also serves as associate director of Community Engagement and Academic Excellence in the Department of Dermatology and associate director of the Pre-Residency Fellowship in Skin of Color Program.

Cross Collaboration and Key Topics at SOCS Scientific Symposium, With Temitayo Ogunleye, MD

 team spoke at the 22nd Annual Skin of Color Society (SOCS) Scientific Symposium, held in conjunction with the 

, with Temitayo Ogunleye, MD, professor of Clinical Dermatology at the University of Pennsylvania and co-chair of the event.

Ogunleye shared her perspective on the forces shaping dermatology today and what she hopes this year's meeting will accomplish. She opened by situating the symposium's theme of championing evidence-based dermatology and collaboration within the broader context of a difficult period for medicine.

“I think that there have been a lot of providers and physicians who are feeling a little bit disillusioned and maybe disappointed about the way things are going,” Ogunleye expressed. “So we thought it was really important to think about ways to reinvigorate our love and care for patients and for ourselves.”

Patient mistrust has been rising, she noted, and many physicians have found themselves feeling disillusioned or disheartened by the direction the field is heading. Against this backdrop, she and her co-organizing committee coordinated the design this program, seeking to reinvigorate clinicians' connection to patients and to their work itself.

, Ogunleye emphasized thinking beyond the presenting issues of patients' and to consider the psychosocial and environmental factors that can also help to shape one’s disease. This type of holistic orientation tied into her mention of personalized medicine, which Ogunleye described as the way of the future in the medical field.

She broadened the definition beyond genetics, arguing that personalized medicine is fundamentally about seeing each patient as an individual and identifying the specific factors modifying their conditions. Cross-specialty collaboration, she argued, is essential to delivering on that promise. 

Turning to the symposium program itself, Ogunleye highlighted several sessions she is particularly looking forward to, including a keynote address on community medicine, a leadership session with Susan Taylor, MD, and panels related to gender-affirming care, pediatric dermatology care, hair loss, and community-based practice models.

Ogunleye singled out 1 session on physician wellness as a topic she considers especially timely. She emphasized burnout as an increasing concern across medicine, driven by competing pressures and, at times, the emotional weight of navigating patient distrust. In her view, those who are not caring for themselves are not in a position to fully care for patients.

Ogunleye closed her discussion by highlighting SOCS’s mission, which she described as directly aligned with the symposium's theme. She emphasized the value of ensuring patients of color are represented in clinical research and addressed across clinical care, education, and community engagement.

https://skinofcolorsociety.org/events/dr-profiles/ogunleye-temitayo-md

Temitayo Ogunleye, MD, co-chair of the Skin of Color Society Scientific Symposium, speaks with HCPLive about the meeting's guiding theme and topics.

Virginia Nuckols, PhD, is a postdoctoral fellow in the Department of Kinesiology and Applied Physiology at the University of Delaware.

Increased Stress Due to Pregnancy Complications Raises Cardiovascular Risk, With Virginia Nuckols, PhD

Women who experience pregnancy complications such as preeclampsia, stillbirth, pre-term birth, or having a baby that is small for gestational age may have a greater risk for 

 later in life, according to a recent study.

The association between stress and cardiovascular disease is well documented. Given the dramatically increased psychosocial stress associated with pregnancy, a wealth of research exists surrounding its cardiovascular impact both immediately and later in life. The present study assessed whether psychosocial stress during and in the years after a first pregnancy was associated with blood pressure levels and 

“We wanted to understand whether or not stress was at all related to the risk for cardiovascular disease and higher blood pressure in these women,” Virginia Nuckols, PhD, a postdoctoral fellow in the Department of Kinesiology and Applied Physiology at the University of Delaware and the lead author of the study, told 

 in an exclusive interview. “We found that women who had higher stress over time and had an adverse pregnancy outcome had higher blood pressure 2-7 years after delivery compared to women who have lower stress.”

Nuckols and colleagues utilized data from the prospective Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be Heart Health Study (nuMoM2b-HHS) cohort. The team assessed perceived stress via the Perceived Stress Scale during the first and third trimester and 2-7 years post-delivery. Latent class trajectory analysis was used to characterize subgroups with similar patterns of perceived stress over time.

Adverse pregnancy outcomes were abstracted from medical charts and ultimately included preterm birth, small-for-gestational-age, stillbirth, and hypertensive disorders of pregnancy. The team also used multivariable regression models to evaluate the independent effects of perceived stress on systolic and diastolic blood pressure, as well as incident hypertension 2-7 years after delivery.

The records of 3322 first-time mothers were included in the study, with an age range of 15-44 years. All included patients did not have high blood pressure before pregnancy. When filling out the Perceived Stress Scale, all patients were asked to note how often they were in situations perceived as uncontrollable, unpredictable, and/or overwhelming in the previous month on a 5-point frequency scale, with higher scores indicating higher stress.

Ultimately, Nuckols and colleagues found that higher stress levels over time in women with adverse pregnancy outcomes were associated with blood pressure roughly 2 mmHg higher than those with low stress; these results were maintained during the years 2-7 after delivery. However, this was not the case among women without adverse pregnancy outcomes. Additionally, patients who experienced moderate to high stress were often younger (25-27 years) and had higher body mass indices and lower educational attainment.

Despite these results, the actual mechanism behind the association between increased stress and increased blood pressure in patients with pregnancy complications remains unclear. The investigators call on future research, suggesting examination of whether stress reduction interventions can meaningfully lower cardiovascular risk.

“There is a lot more work to be done to understand effective and pragmatic interventions for this population of women who are experiencing novel stressors as they transition to motherhood,” Nuckols said. “We need to improve general awareness for clinicians that stress could play a role in cardiovascular risk, as well as communicating that to patients when they enter.”

Editors’ Note: Nuckols reports no relevant disclosures.

Beveridge K. Pregnancy complications impact women’s stress levels and cardiovascular risk long after delivery. 

. March 9, 2026. Accessed March 26, 2026. 

https://newsroom.heart.org/news/pregnancy-complications-impact-womens-stress-levels-and-cardiovascular-risk-long-after-delivery

Nuckols VR, Barone Gibbs B, Brewer BC, et al. Stress trajectory and hypertension 2 to 7 years after delivery: A NUMOM2B-HHS Study. 

Nuckols discusses her recent study highlighting a correlation between pregnancy complications, increased psychosocial stress, and cardiovascular disease risk.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Sofia Holmqvist-Jämsén, PhD, from the University of Helsinki

Population study links respiratory allergies to hoarseness, throat clearing, and vocal fatigue, with greater symptom burden in women and unified airway implications.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Respiratory Allergies Linked to Vocal Symptoms, With Holmqvist-Jämsén, PhD

Christopher Kramer, MD, FACC, is the current president of the American College of Cardiology.

Kramer, the president of the American College of Cardiology, discusses the organization’s recent movement to adapt rapidly growing AI technology to clinical care.

Artificial Intelligence in Cardiology: The ACC’s Implementation Pipeline, With Christopher Kramer, MD, FACC

Akl Fahed, MD, MPH, Interventional Cardiologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.

Fahed explains how a multi-ancestry metabolic poly genetic risk score from over 8.5 million individuals points to the utility of global collaboration in genetic research. 


Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Multi-Ancestry Genetic Risk Score Shows Value of Global Collaboration in Metabolic Disease, With Akl Fahed, MD, MPH

New research identifies dietary epitopes driving oral tolerance, offering insight into Treg responses, early exposure, and future food allergy therapies.

Food Allergy

Dietary Epitopes Drive Oral Tolerance, With Jamie Blum, PhD

Experts discuss therapeutic switching in patients already on biologic therapy and adherence challenges specific to oral agents.

Managing Established Patients: Switching, Adherence, Spontaneous Remission, and Treatment Duration

Experts address how quickly clinicians should escalate from antihistamines to step-up therapy and examine remibrutinib's clinical trial data on speed of response.

Antihistamine Escalation, Time to Step-Up, and Remibrutinib's Rapid Onset of Action 

Bhatt shares his thoughts on the recently released dyslipidemia guidelines, highlighting the return of goal-based LDL-C therapy and Lp(a) receiving a COR 1 suggestion.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Updated ACC/AHA Dyslipidemia Guidelines Incorporate LDL-C Goals, Lp(a) Focus, With Deepak Bhatt, MD, MPH

Allergist-immunologist at Yale New Haven Hospital

Su emphasized how care should be shifted to reflect known impacts of NNAALs on obstetric care.

The Case for Delabeling NNAALs in Obstetric Care, With Chang Su, MD

Andres Gelrud, MD, is a gastroenterologist at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida

Gerlud explains why exocrine pancreatic insufficiency is often missed, even in high-risk patients. 


Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Why Exocrine Pancreatic Insufficiency Is Frequently Underdiagnosed, With Andres Gelrud, MD

Piotr Witkowski, MD, PhD, is a professor of surgery in the Transplantation Institute at the University of Chicago.

Witkowski discusses the data presented at ATTD 2026, highlighting the investigative anti-CD40L monoclonal antibody in facilitating insulin independence.

Latest News

FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes

Addressing Complex Cases in Dermatology at SOCS Scientific Symposium, With Janiene Luke, MD

From APOL1 to Biomarkers, Glomerular Disease Research Is Redefining Kidney Care, With Tobias Huber, MD, Barbara Gillespie, MD

Cross Collaboration and Key Topics at SOCS Scientific Symposium, With Temitayo Ogunleye, MD

Increased Stress Due to Pregnancy Complications Raises Cardiovascular Risk, With Virginia Nuckols, PhD